Double-masked, placebo-controlled, randomized trial of lutein and antioxidant supplementation in the intervention of atrophic age-related macular degeneration: the Veterans LAST study (Lutein Antioxidant Supplementation Trial).
Double-masked, placebo-controlled, randomized trial of lutein and antioxidant supplementation in the intervention of atrophic age-related macular degeneration: the Veterans LAST study (Lutein Antioxidant Supplementation Trial).
复制标题
DOI：
10.1016/s1529-1839(04)70049-4
复制
发表时间：
2004-04-01
期刊：
影响因子：
--
通讯作者：
Nyland, Jill
中科院分区：
文献类型：
--
作者：
Richer, Stuart;Stiles, William;Nyland, Jill
背景：老年性黄斑变性(ARMD)是西方老龄化社会中导致视力丧失的主要原因。叶黄素抗氧化剂补充试验(LAST)的目的是确定叶黄素或叶黄素与抗氧化剂、维生素和矿物质一起营养补充是否能改善萎缩性ARMD的视觉功能和症状。方法：该研究是一项前瞻性、为期12个月的随机、双盲、安慰剂对照试验，于1999年8月至2001年5月在中西部一家城市退伍军人管理局医院进行。芝加哥地区两家退伍军人医疗机构的眼科医生推荐了90名患有萎缩性ARMD的患者。结果：1组患者服用叶黄素10 mg(L)，2组服用叶黄素10 mg/抗氧化剂/维生素和矿物质广谱补充剂(L/A)，3组服用麦芽糊精安慰剂(P)，为期12个月。结果：1组L和2 L/A平均眼黄斑色素光密度较基线增加约0.09log单位，斯内伦等效视力提高5.4字母L和3.5字母L/A，并改善对比敏感度。VFO-14问卷显示，L/A组患者在4个月时主观眩光恢复接近显著水平。服用安慰剂的患者(第3组)的任何测量结果均无显著变化。结论：在本研究中，单独服用叶黄素或叶黄素与其他营养素联合使用均能改善视功能。需要更多的男女患者和更长的时间来评估叶黄素或叶黄素与广泛的抗氧化剂、维生素和矿物质在治疗萎缩性老年性黄斑变性中的长期效果。
BACKGROUND: Age-related macular degeneration (ARMD) is the leading cause of vision loss in aging Westem societies. The objective of the lutein antioxidant supplementation trial (LAST) is to determine whether nutritional supplementation with lutein or lutein together with antioxidants, vitamins, and minerals, improves visual function and symptoms in atrophic ARMD.METHODS: The study was a prospective, 12-month, randomized, double-masked, placebo-controlled trial conducted at an urban midwestern Veterans Administration Hospital from August 1999 to May 2001. Ninety patients with atrophic ARMD were referred by ophthalmologists at two Chicago-area veterans medical facilities. Patients in Group 1 received lutein 10 mg (L); in Group 2, a lutein 10 mg/antioxidants/vitamins and minerals broad spectrum supplementation formula (L/A); and in Group 3, a maltodextrin placebo (P) over 12 months.RESULTS: In Groups 1 L and 2 L/A, mean eye macular pigment optical density increased approximately 0.09 log units from baseline, Snellen equivalent visual acuity improved 5.4 letters for Group 1 L and 3.5 letters for Group 2 L/A, and contrast sensitivity improved. There was a net subjective improvement in Amsler grid in Group 1 L. VFO-14 questionnaires conceming subjective glare recovery were nearly significant at 4 months for Group 2 L/A. Patients who received the placebo (Group 3) had no significant changes in any of the measured findings.CONCLUSION: In this study, visual function is improved with lutein alone or lutein together with other nutrients. Further studies are needed with more patients, of both genders, and for longer periods of time to assess long-term effects of lutein or lutein together with a broad spectrum of antioxidants, vitamins, and minerals in the treatment of atrophic age-related macular degeneration.